The compound doesn’t touch dopamine receptors, unlike many antipsychotics, and avoids the sedation and weight gain often caused by drugs like clozapine. Its affinity for serotonin receptors is ...

The mind-expanding drugs may help heal many mental health conditions. But studies haven’t actually proved that yet.

MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD ...

LSD was first developed in 1938 by Swiss researcher Albert Hoffman, who famously took the mother of all acid doses on April 19, 1943, before he flew his bicycle home from the lab.

Previous studies have shown that the hallucinogenic effects of LSD are mediated to a large extent by the signaling pathway involving the β-arrestin-2 protein. Thus, it is possible that compounds ...

The bizarre effects it had on the mind suggested that the compound, which he named LSD, might provide insight into debilitating mental conditions, like schizophrenia. To have such mind-altering ...